— Know what they know.
Not Investment Advice

HOWL NASDAQ

Werewolf Therapeutics, Inc.
1W: -3.3% 1M: -7.0% 3M: +190.0% YTD: +43.9% 1Y: -52.4% 3Y: -58.2% 5Y: -94.8%
$0.93
+0.05 (+5.29%)
 
Weekly Expected Move ±6.5%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 50 · $45.1M mcap · 42M float · 1.49% daily turnover · Short 34% of daily vol

Balance Sheet Trends

Total Assets
$69M -45.3% ▼
5Y CAGR: -6.4%
Total Liabilities
$45M -16.7% ▼
5Y CAGR: +44.1%
Shareholders Equity
$25M -66.2% ▼
5Y CAGR: -22.6%
Cash & Investments
$58M -47.8% ▼
5Y CAGR: -8.9%
Total Debt
$9M -74.6% ▼
5Y CAGR: +30.0%
Net Debt
-$49M +34.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$158M$129M$134M$111M$58M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$158M$129M$134M$111M$58M
Net Receivables$0$7M$1M$0$0
Inventory$0$0$0$0$0
Other Current Assets$100K$4M$3M$2M$635K
Total Current Assets$161M$140M$138M$113M$59M
Property, Plant & Equip.$16M$17M$15M$12M$10M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$1M$21M$1M$901K
Other Non-Current Assets$2M$1M$594K$320K$5K
Total Non-Current Assets$18M$20M$36M$14M$11M
Total Assets$179M$160M$175M$127M$69M
— Liabilities —
Accounts Payable$2M$1M$1M$3M$754K
Short-Term Debt$0$0$7M$0$2M
Deferred Revenue$0$7M$907K$0$0
Other Current Liabilities$163K$11M$4M$11M$34M
Total Current Liabilities$12M$24M$19M$15M$36M
Long-Term Debt$0$0$33M$26M$0
Other Non-Current Liab.$0$1M$433K$3M$759K
Total Non-Current Liabilities$15M$14M$44M$38M$8M
Total Liabilities$26M$38M$63M$54M$45M
— Equity —
Common Stock$2K$3K$4K$5K$5K
Retained Earnings-$253M-$307M-$344M-$415M-$475M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$153M$122M$111M$73M$25M
Total Liabilities & Equity$179M$160M$175M$127M$69M
— Key Metrics —
Total Debt$16M$15M$52M$37M$9M
Net Debt-$142M-$115M-$82M-$74M-$49M
Total Investments$0$1M$21M$1M$901K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms